| 109.54 Net Asset Value | -0.55% 1 Day | +30.70% Year-to-Date | Overall Morningstar Rating |
| Health Style or Category | No Load Sales Expenses | 0.99% Expense Ratio | Above Average Morningstar Risk Rating™ |
| 1 month | +3.46% | 3 years | +30.16% | |
| 3 months | +20.92% | 5 years | -- | |
| 1 year | +45.13% | Since inception | +23.59% |
| FTDZX | Category | |
|---|---|---|
| Performance 5-yr return | -- | +12.10% |
| Expense ratio | 0.99% | 1.55% |
| Risk 5 year sharpe ratio | 0.92 | 0.71 |
| Net assets | $679.3M | $1.5B |
| Average market cap | $7.6B | $19.4B |
| Average P/E | 26.2 | 21.6 |
| Portfolio turnover | 47% | 47% |
There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.
| Fund family | Franklin Templeton Investment Funds |
| Fund manager & tenure | Evan McCulloch / 15 Years |
| Minimal initial investment | $0.00 |
| Minimum IRA investment | -- |
| Other | 100.00% |
| U.S. stock | -- |
| International stock | -- |
| Fixed income | -- |
| Cash | -- |
| Healthcare | 100.00% |
| Business service | 0.00% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
| GILD Gilead Sciences Inc | 10.43% |
| CELG Celgene Corporation | 9.40% |
| BIIB Biogen Idec Inc | 6.39% |
| AMGN Amgen Inc | 6.01% |
| ALXN Alexion Pharmaceuticals, Inc. | 3.72% |
| VRTX Vertex Pharmaceuticals | 3.55% |
| MDVN Medivation, Inc. | 2.65% |
| ARIA Ariad Pharmaceuticals | 2.36% |
| BMRN Biomarin Pharmaceutical, Inc. | 2.14% |
| PCYC Pharmacyclics, Inc. | 2.00% |
.
